Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.…
Wedbush keeps Climb Bio on Best Ideas List, raises price target
Climb Bio (NASDAQ: CLYM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 28 employees.
The shares were at 9.190 USD on 20 November 2026, up 402.2% over 52 weeks. Its 52-week range is 1.635 USD to 18.14 USD: the price is 49.3% below the high and 462.1% above the low.
Its market capitalisation is 539.80M USD.
Climb Bio reports return on equity of -37.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 204.36M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 15 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 28.40 USD is 209.0% above the current price. The next earnings report is expected on 18 March 2027.